Profils clinique, électrophysiologique et biologique des neuropathies anti-MAG en fonction du statut mutationnel MYD88 et de l’hémopathie sous-jacente
Alexandre Guérémy(Hôpital de la Timone), José Boucraut(Institut de Neurosciences des Systèmes), Ludivine Kouton(Hôpital de la Timone), Émilien Delmont(Assistance Publique Hôpitaux de Marseille), Laure Farnault(Aix-Marseille Université), John Boudjarane, Shahram Attarian(Aix-Marseille Université), Aude-Marie Grapperon, Jean Gabert(Hôpital Nord), Étienne Fortanier(Laboratoire National de Référence)
Cited by 0
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials
|Journal of Clinical Oncology|2003|606
Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial
|Journal of Clinical Oncology|2004|547
Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio‐Oncology Guidelines
|Journal of the American Heart Association|2020|298